Global Psychedelic Drugs Market - Industry Trends and Forecast to 2029

Description

List of Tables

Global psychedelic drugs market is projected to register a substantial CAGR of 13.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Global Psychedelic Drugs Market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy), Country (North America, Europe, Asia-Pacific, Middle East and Africa and South America) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the global psychedylic drugs market are:

Growing acceptance of psychedelic drugs for treating depression

Increasing Prevalence Of Depression And Mental Disorders

Market Players:

The key market players for global psychedelic drugs market are listed below:

Jazz Pharmaceuticals, Inc.

Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)

Hikma Pharmaceuticals PLC

COMPASS

Verrian

Pfizer Inc.

F. Hoffmann-La Roche Ltd

Avadel

Celon Pharma SA.

Cybin Corp.

GH Research

Entheon Biomedical Corp

PharmaTher Holdings Ltd.

NRx Pharmaceuticals, Inc.

usonainstitute.org

1 INTRODUCTION 25

1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.3 OVERVIEW OF GLOBAL PSYCHEDELIC DRUGS MARKET 25
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 27

2 MARKET SEGMENTATION 30

2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 TYPE LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET END USER COVERAGE GRID 39
2.11 VENDOR SHARE ANALYSIS 40
2.12 SECONDARY SOURCES 41
2.13 ASSUMPTIONS 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHT 46

4.1 PIPELINE ANALYSIS 48
4.2 PESTEL ANALYSIS 50
4.3 PORTER'S FIVE FORCES MODEL 51

5 REGULATORY FRAMEWORK: GLOBAL PSYCHEDELIC DRUGS MARKET 52

5.1 REGULATORY SCENARIO IN THE U.S. 52
5.2 REGULATORY SCENARIO IN THE U.K. 53
5.3 REGULATORY SCENARIO IN INDIA 54
5.4 REGULATORY SCENARIO IN UAE 54
5.5 REGULATORY SCENARIO IN AFRICA 55
5.6 REGULATORY SCENARIO IN BRAZIL 55

6 MARKET OVERVIEW 57

6.1 DRIVERS 59
- 6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION 59
- 6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 61
- 6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH 64
- 6.1.4 ONGOING CLINICAL TRIALS 65
- 6.1.5 RISE IN PRODUCT APPROVALS 66
6.2 RESTRAINTS 66
- 6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 66
- 6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 69
- 6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 70
6.3 OPPORTUNITIES 71
- 6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 71
- 6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 73
- 6.3.3 UPCOMING REHABILITATION CENTERS 74
- 6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 75
6.4 CHALLENGES 75
- 6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 75
- 6.4.2 RISE IN ILLEGAL ALTERNATIVES 77
- 6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 77

7 COVID-19 IMPACT ON THE GLOBAL PSYCHEDELIC DRUGS MARKET 78

7.1 IMPACT ON PRICE 78
7.2 IMPACT ON DEMAND 78
7.3 IMPACT ON SUPPLY CHAIN 79
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 79
7.5 CONCLUSION 80

8 GLOBAL PSYCHEDELIC DRUGS MARKET, BY TYPE 81

8.1 OVERVIEW 82
8.2 EMPATHOGENS 85
8.3 DISSOCIATIVES 86
8.4 OTHERS 87

9 GLOBAL PSYCHEDELIC DRUGS MARKET, BY SOURCE 88

9.1 OVERVIEW 89
9.2 SYNTHETIC 92
9.3 NATURAL 93

10 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUGS 94

10.1 OVERVIEW 95
10.2 GAMMA-HYDROXYBUTYRIC ACID 98
10.3 KETAMINE 99
10.4 PSILOCYBIN 100
10.5 OTHERS 101

11 GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION 102

11.1 OVERVIEW 103
11.2 NARCOLEPSY 106
11.3 TREATMENT RESISTANT DEPRESSION 107
11.4 MAJOR DEPRESSIVE DISORDER 108
11.5 OPIATE ADDICTION 109
11.6 POST-TRAUMATIC STRESS DISORDER 110
11.7 OTHERS 111

12 GLOBAL PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 112

12.1 OVERVIEW 113
12.2 ORAL 116
12.3 INHALATION 117
12.4 INJECTABLE 118

13 GLOBAL PSYCHEDELIC DRUGS MARKET, BY END USER 119

13.1 OVERVIEW 120
13.2 HOSPITALS 123
13.3 SPECIALTY CLINICS 124
13.4 HOMECARE 125
13.5 OTHERS 126

14 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 127

14.1 OVERVIEW 128
14.2 HOSPITALS PHARMACY 131
14.3 RETAIL PHARMACY 132
14.4 ONLINE PHARMACY 133

15 GLOBAL PSYCHEDELIC DRUGS MARKET, BY REGION 134

15.1 OVERVIEW 135
15.2 NORTH AMERICA 141
- 15.2.1 U.S. 148
- 15.2.2 CANADA 150
- 15.2.3 MEXICO 152
15.3 EUROPE 154
- 15.3.1 GERMANY 163
- 15.3.2 U.K. 165
- 15.3.3 FRANCE 168
- 15.3.4 ITALY 170
- 15.3.5 SPAIN 173
- 15.3.6 RUSSIA 175
- 15.3.7 POLAND 178
- 15.3.8 SWITZERLAND 181
- 15.3.9 NETHERLANDS 184
- 15.3.10 HUNGARY 187
- 15.3.11 AUSTRIA 190
- 15.3.12 NORWAY 193
- 15.3.13 IRELAND 196
- 15.3.14 BELGIUM 199
- 15.3.15 LITHUANIA 202
- 15.3.16 REST OF EUROPE 205
15.4 ASIA-PACIFIC 206
- 15.4.1 INDIA 214
- 15.4.2 AUSTRALIA 217
- 15.4.3 SOUTH KOREA 220
- 15.4.4 SINGAPORE 223
- 15.4.5 MALAYSIA 226
15.5 MIDDLE EAST & AFRICA 229
- 15.5.1 SAUDI ARABIA 237
- 15.5.2 ISRAEL 240
- 15.5.3 EGYPT 243
- 15.5.4 UAE 246
- 15.5.5 SOUTH AFRICA 248
15.6 SOUTH AMERICA 251
- 15.6.1 BRAZIL 259
- 15.6.2 ARGENTINA 262
- 15.6.3 REST OF SOUTH AMERICA 265

16 GLOBAL PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 266

16.1 COMPANY SHARE ANALYSIS: GLOBAL 266
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 267
16.3 COMPANY SHARE ANALYSIS: EUROPE 268
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 269

17 SWOT ANALYSIS 270

18 COMPANY PROFILE 271

18.1 JAZZ PHARMACEUTICALS, INC. 271
- 18.1.1 COMPANY SNAPSHOT 271
- 18.1.2 REVENUE ANALYSIS 272
- 18.1.3 COMPANY SHARE ANALYSIS 272
- 18.1.4 PRODUCT PORTFOLIO 272
- 18.1.5 RECENT DEVELOPMENTS 273
18.2 PFIZER INC. 274
- 18.2.1 COMPANY SNAPSHOT 274
- 18.2.2 REVENUE ANALYSIS 274
- 18.2.3 COMPANY SHARE ANALYSIS 275
- 18.2.4 PRODUCT PORTFOLIO 275
- 18.2.5 RECENT DEVELOPMENTS 275
18.3 F. HOFFMANN- LA ROCHE LTD 276
- 18.3.1 COMPANY SNAPSHOT 276
- 18.3.2 REVENUE ANALYSIS 276
- 18.3.3 COMPANY SHARE ANALYSIS 277
- 18.3.4 PRODUCT PORTFOLIO 277
- 18.3.5 RECENT DEVELOPMENT 277
18.4 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 278
- 18.4.1 COMPANY SNAPSHOT 278
- 18.4.2 COMPANY SHARE ANALYSIS 278
- 18.4.3 PRODUCT PORTFOLIO 279
- 18.4.4 RECENT DEVELOPMENT 279
18.5 AVADEL 280
- 18.5.1 COMPANY SNAPSHOT 280
- 18.5.2 PRODUCT PORTFOLIO 280
- 18.5.3 RECENT DEVELOPMENT 280
18.6 CELON PHARMA SA 281
- 18.6.1 COMPANY SNAPSHOT 281
- 18.6.2 PRODUCT PORTFOLIO 281
- 18.6.3 RECENT DEVELOPMENT 281
18.7 COMPASS 282
- 18.7.1 COMPANY SNAPSHOT 282
- 18.7.2 PRODUCT PORTFOLIO 282
- 18.7.3 RECENT DEVELOPMENTS 282

18.8 CYBIN CORP. 283
- 18.8.1 COMPANY SNAPSHOT 283
- 18.8.2 PRODUCT PORTFOLIO 283
- 18.8.3 RECENT DEVELOPMENTS 283
18.9 ENTHEON BIOMEDICAL CORP 284
- 18.9.1 COMPANY SNAPSHOT 284
- 18.9.2 PRODUCT PORTFOLIO 284
- 18.9.3 RECENT DEVELOPMENT 284
18.10 GH RESEARCH 285
- 18.10.1 COMPANY SNAPSHOT 285
- 18.10.2 PRODUCT PORTFOLIO 285
- 18.10.3 RECENT DEVELOPMENT 285
18.11 HIKMA PHARMACEUTICALS PLC 286
- 18.11.1 COMPANY SNAPSHOT 286
- 18.11.2 REVENUE ANALYSIS 286
- 18.11.3 PRODUCT PORTFOLIO 287
- 18.11.4 RECENT DEVELOPMENTS 287
18.12 NRX PHARMACEUTICALS, INC. 288
- 18.12.1 COMPANY SNAPSHOT 288
- 18.12.2 PRODUCT PORTFOLIO 288
- 18.12.3 RECENT DEVELOPMENT 288
18.13 PHARMATHER HOLDINGS LTD. 289
- 18.13.1 COMPANY SNAPSHOT 289
- 18.13.2 PRODUCT PORTFOLIO 289
- 18.13.3 RECENT DEVELOPMENT 289
18.14 VERRIAN 290
- 18.14.1 COMPANY SNAPSHOT 290
- 18.14.2 PRODUCT PORTFOLIO 290
- 18.14.3 RECENT DEVELOPMENT 290
18.15 USONAINSTITUTE.ORG 291
- 18.15.1 COMPANY SNAPSHOT 291
- 18.15.2 PRODUCT PORTFOLIO 291
- 18.15.3 RECENT DEVELOPMENT 291

19 QUESTIONNAIRE 292

20 RELATED REPORTS 296

LIST OF FIGURES

FIGURE 1 GLOBAL PSYCHEDELIC DRUGS MARKET: SEGMENTATION 30
FIGURE 2 GLOBAL PSYCHEDELIC DRUGS MARKET : DATA TRIANGULATION 33
FIGURE 3 GLOBAL PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS 34
FIGURE 4 GLOBAL PSYCHEDELIC DRUGS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 35
FIGURE 5 GLOBAL PSYCHEDELIC DRUGS MARKET: COMPANY RESEARCH ANALYSIS 35
FIGURE 6 GLOBAL PSYCHEDELIC DRUGS MARKET: MULTIVARIATE MODELLING 36
FIGURE 7 GLOBAL PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS 37
FIGURE 8 GLOBAL PSYCHEDELIC DRUGS MARKET: DBMR MARKET POSITION GRID 38
FIGURE 9 GLOBAL PSYCHEDELIC DRUGS MARKET: END USER COVERAGE GRID 39
FIGURE 10 GLOBAL PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS 40
FIGURE 11 GLOBAL PSYCHEDELIC DRUGS MARKET: SEGMENTATION 44
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PSYCHEDELIC DRUGS MARKET GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 45
FIGURE 13 RISING AWARENESS TOWARDS MERANTAL HEALTH DRIVING THE GLOBAL PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 46
FIGURE 14 EMPATHOGENS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PSYCHEDELIC DRUGS MARKET IN 2022 & 2029 46
FIGURE 15 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR PSYCHEDELIC DRUGS MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029 47
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL PSYCHEDELIC DRUGS MARKET 58
FIGURE 17 MENTAL ILLNESS AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS 62
FIGURE 18 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS 63
FIGURE 19 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY GENDER 64
FIGURE 20 GLOBAL PSYCHEDELIC DRUGS MARKET: BY TYPE, 2021 82
FIGURE 21 GLOBAL PSYCHEDELIC DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION) 83
FIGURE 22 GLOBAL PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2022-2029) 83
FIGURE 23 GLOBAL PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE 84
FIGURE 24 GLOBAL PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2021 89
FIGURE 25 GLOBAL PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2022-2029 (USD MILLION) 90
FIGURE 26 GLOBAL PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2022-2029) 90
FIGURE 27 GLOBAL PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE 91
FIGURE 28 GLOBAL PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2021 95
FIGURE 29 GLOBAL PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION) 96
FIGURE 30 GLOBAL PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2022-2029) 96
FIGURE 31 GLOBAL PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE 97
FIGURE 32 GLOBAL PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2021 103
FIGURE 33 GLOBAL PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 104
FIGURE 34 GLOBAL PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2022-2029) 104
FIGURE 35 GLOBAL PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE 105
FIGURE 36 GLOBAL PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021 113
FIGURE 37 GLOBAL PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 114
FIGURE 38 GLOBAL PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 114
FIGURE 39 GLOBAL PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 115
FIGURE 40 GLOBAL PSYCHEDELIC DRUGS MARKET: BY END USER, 2021 120
FIGURE 41 GLOBAL PSYCHEDELIC DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION) 121
FIGURE 42 GLOBAL PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2022-2029) 121
FIGURE 43 GLOBAL PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE 122
FIGURE 44 GLOBAL PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021 128
FIGURE 45 GLOBAL PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 129
FIGURE 46 GLOBAL PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 129
FIGURE 47 GLOBAL PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 130
FIGURE 48 GLOBAL PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021) 136
FIGURE 49 GLOBAL PSYCHEDELIC DRUGS MARKET: BY REGION (2021) 138
FIGURE 50 GLOBAL PSYCHEDELIC DRUGS MARKET: BY REGION (2022 & 2029) 138
FIGURE 51 GLOBAL PSYCHEDELIC DRUGS MARKET: BY REGION (2021 & 2029) 139
FIGURE 52 GLOBAL PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029) 139
FIGURE 53 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021) 142
FIGURE 54 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021) 144
FIGURE 55 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029) 144
FIGURE 56 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029) 145
FIGURE 57 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029) 145
FIGURE 58 EUROPE PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021) 155
FIGURE 59 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021) 157
FIGURE 60 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029) 157
FIGURE 61 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029) 158
FIGURE 62 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029) 159
FIGURE 63 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021) 207
FIGURE 64 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021) 209
FIGURE 65 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029) 209
FIGURE 66 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029) 210
FIGURE 67 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029) 210
FIGURE 68 MIDDLE EAST & AFRICA PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021) 230
FIGURE 69 MIDDLE EAST & AFRICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021) 232
FIGURE 70 MIDDLE EAST & AFRICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029) 232
FIGURE 71 MIDDLE EAST & AFRICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029) 233
FIGURE 72 MIDDLE EAST & AFRICA PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029) 233
FIGURE 73 SOUTH AMERICA PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021) 252
FIGURE 74 SOUTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021) 254
FIGURE 75 SOUTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029) 254
FIGURE 76 SOUTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029) 255
FIGURE 77 SOUTH AMERICA PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029) 255
FIGURE 78 GLOBAL PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%) 266
FIGURE 79 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%) 267
FIGURE 80 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%) 268
FIGURE 81 ASIA-PACIFIC PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%) 269